Intra Articular Treatment of Disease-Modifying Nanomedicines for Osteoarthritis
Abstract
We hypothesize (1) that IA administration of drugs targeting both Flt1 and Flk1 simultaneously will elicit dual effects eliciting (a) rapid pain reduction and (b) inhibition of cartilage degeneration, and (2) that a single IA administration of nano-PAZIII (nanotechnology-based drug formulation of pazopanib) will provide prolonged and sustained drug efficacy for >16 weeks controlling pain and OA disease progression, simultaneously, in our preclinical OA animal model. We will rigorously test our hypotheses: Aim 1, we will evaluate rapid pain reduction and halted joint pathology by targeting Flt1 and/or Flk1 by weekly IA treatment with either individual monoclonal antibodies (mAbs) or combinations of mAbs over the course of disease progression (inflammatory-, early- and advanced OA).
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1193083
Entities
People
- Hee-jeong Sampen
- Kaige Ma
- Ying Liu
Organizations
- University of Chicago